Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular complications in Chuvash polycythemia.

Victor R Gordeuk1, Josef T Prchal

  • 1Department of Medicine and Center for Sickle Cell Disease, Howard University, Washington, District of Columbia, USA. vgordeuk@howard.edu

Seminars in Thrombosis and Hemostasis
|May 5, 2006
PubMed
Summary

Chuvash polycythemia, caused by a VHL gene mutation, leads to increased red blood cells and various vascular issues. This condition is linked to thrombosis and bleeding but not cancer, requiring further study for effective treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.

Blood advances·2026
Same author

Why JAK2-mutated neutrophils deserve to be on center stage in polycythemia vera.

Annals of hematology·2026
Same author

Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.

Blood advances·2026
Same author

Autosomal Dominant Erythrocytosis Caused by Non-Renal Erythropoietin (EPO) Due to EPO c.-136 G>A Germline Mutation.

American journal of hematology·2026
Same author

Do Andean Aymara High-Altitude-Enriched Genetic Variants Protect Europeans Against Acute Mountain Sickness?

Acta physiologica (Oxford, England)·2026
Same author

VHL, transferrin, and erythropoietin in the regulation of hepcidin.

HemaSphere·2025

Area of Science:

  • Genetics and Molecular Biology
  • Hematology
  • Vascular Biology

Background:

  • Chuvash polycythemia is a distinct erythrocytosis linked to a specific germline mutation (598C>T) in the von Hippel-Lindau (VHL) gene.
  • This mutation causes hypoxia-inducible factor-1alpha (HIF-1α) to be upregulated even under normal oxygen conditions, affecting numerous genes.
  • While endemic to the Chuvash population, the VHL 598C>T mutation is found globally, suggesting a common ancestral origin.

Purpose of the Study:

  • To comprehensively describe the clinical phenotype and associated conditions of Chuvash polycythemia.
  • To investigate the long-term health consequences, including vascular complications and cancer risk, in individuals with this genetic mutation.
  • To evaluate the efficacy of current therapeutic approaches and identify areas for future research.

Related Experiment Videos

Main Methods:

  • Utilized matched-cohort and case-control analyses to compare individuals with Chuvash polycythemia to control groups.
  • Collected and analyzed data on clinical characteristics, blood parameters, serum markers, and patient outcomes.
  • Reviewed retrospective treatment data for phlebotomy and aspirin, and considered prospective study designs.

Main Results:

  • VHL 598C>T homozygosity is associated with reduced blood pressure, varicose veins, vertebral hemangiomas, and lower white blood cell and platelet counts.
  • Elevated levels of vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor-1 (PAI-1) were observed.
  • Significant associations were found with arterial and venous thrombosis, major bleeding events, cerebrovascular incidents, and increased premature mortality.
  • Classical VHL tumor manifestations (hemangioblastomas, renal carcinomas, pheochromocytomas) and increased cancer risk were notably absent.

Conclusions:

  • Chuvash polycythemia presents a unique clinical profile distinct from classical VHL disease, characterized by vascular complications and thrombotic/bleeding risks without an increased cancer predisposition.
  • Current retrospective data suggest limited benefit from phlebotomy or aspirin, highlighting the need for prospective therapeutic trials.
  • Further research into the vascular manifestations of this condition offers valuable insights into thrombophilia, bleeding disorders, and cancer protection mechanisms.